|
Back to:
Nitrofurantoin
(Last updated March 2026)
Figure 1. The molecular diagram of Nitrofurantoin.
CSP studies
| REFCODE | |
| Formula | C8 H6 N4 O5 |
| Common Name | Nitrofurantoin |
| IUPAC Systematic Name | 1-{[(5-nitrofuran-2(5H)-ylidene)methyl]amino}imidazolidine-2,4-dione |
| Other Names | |
| CSD Refcodes | LABJON06, LABJON07 |
| |
| Search Identifier | |
| Scientist | Agris Berzins |
| Date | 2018 |
| Publication | Trimdale-Deksne A, Kons A, Orola, L, Mishnev A, Stepanovs D, Mazur L, Skiba M, Dudek MK, Fantozzi N, Virieux D, et al. Crystal Growth & Design 2023, 23 (2), 930-945 |
| Energy model | |
| Study_ID | 10 |
| Programs | CrystalPredictor, CrystalOptimizer, DMACRYS (2.3.0) |
| Location on S Drive | \CHEMISTRY_CPOSS\Agris\Nitrofurantoin |
| Potential Description | CrystalOptimizer MO62X/6-31G(d,p) intramolecular + GDMA2.2(MO62X/6-31G(d,p)) DMA + FIT |
| Intramolecular Description | M062X/6-31G(d,p) |
Figure 2. Lattice Energy Landscape of Nitrofurantoin. Energy model A1.
CSD structures (CSD version 6.01 with Feb 2026 update)
Table 1. Crystallographic information and experimental information of CSD entries for Nitrofurantoin. Different polymorphs, as ascertained by structure matching of 20 molecule coordination sphere in Mercury, are coloured differently. Reference polymorphs are outlined in bold.
| REFCODE | Spacegroup | Z' | a / Å | b / Å | c / Å | α / ° | β / ° | γ / ° | density / g cm-3 | Form | R factor | T / K | Year | Comment / reference | REFCODE |
| LABJON | P21/n | 1.0 | 7.845 | 6.462 | 18.92 | 90.0 | 93.18 | 90.0 | 1.6518 | monoclinic beta polymorph | 4.0 | None | 1993 | 10.1107/S010827019201062X | LABJON |
| LABJON01 | P-1 | 1.0 | 6.774 | 7.795 | 9.803 | 106.68 | 104.09 | 92.29 | 1.6562 | triclinic alpha polymorph | 3.4 | None | 1993 | 10.1007/BF01247241 | LABJON01 |
| LABJON02 | P21/n | 1.0 | 7.84 | 6.486 | 18.911 | 90.0 | 93.17 | 90.0 | 1.6475 | monoclinic beta polymorph | 5.3 | None | 1993 | 10.1007/BF01247241 | LABJON02 |
| LABJON04 | P21/c | 1.0 | 7.849 | 6.5 | 20.0570 | 90.0 | 109.675 | 90.0 | 1.6417 | P21/c polymorph | 6.460 | 293 K | 2015 | 10.4236/ojic.2015.53008 | LABJON04 |
| LABJON05 | P-1 | 1.0 | 6.78060 | 7.79320 | 9.81590 | 106.699 | 104.105 | 92.306 | 1.6531 | triclinic alpha polymorph | 3.409 | 290 K | 2023 | 10.1021/acs.cgd.3c00033 | LABJON05 |
| LABJON06 | P-1 | 1.0 | 6.78790 | 7.6074 | 9.7707 | 106.991 | 103.821 | 92.294 | 1.6999 | triclinic alpha polymorph | 3.130 | 100 K | 2023 | 10.1021/acs.cgd.3c00033 | LABJON06 |
| LABJON07 | P21/n | 1.0 | 7.6855 | 6.46500 | 18.8252 | 90.0 | 91.869 | 90.0 | 1.6920 | monoclinic beta polymorph | 2.98 | 100 K | 2023 | 10.1021/acs.cgd.3c00033 | LABJON07 |
| LABJON08 | P21/n | 1.0 | 7.83970 | 6.48600 | 18.943 | 90.0 | 92.754 | 90.0 | 1.6441 | monoclinic beta polymorph | 6.81 | 290 K | 2023 | 10.1021/acs.cgd.3c00033 | LABJON08 |
|